Advanced search
1 file | 541.89 KB

Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men

Author
Organization
Abstract
Context: Strontium ranelate reduces vertebral and nonvertebral fracture risk in postmenopausal osteoporosis. Objective: The objective of this study was to determine the efficacy and safety of strontium ranelate in osteoporosis in men over 2 years (main analysis after 1 year). Design: This was an international, unbalanced (2: 1), double-blind, randomized placebo-controlled trial (MALEO [MALE Osteoporosis]). Setting: This international study included 54 centers in 14 countries. Participants: Participants were 261 white men with primary osteoporosis. Intervention: Strontium ranelate at 2 g/d (n = 174) or placebo (n = 87) was administered. Main Outcome Measures: Lumbar spine (L2-L4), femoral neck, and total hip bone mineral density (BMD), biochemical bone markers, and safety were measured. Results: Baseline characteristics were similar in both groups in the whole population (age, 72.9 +/- 6.0 years; lumbar spine BMD T-score, -2.7 +/- 1.0; femoral neck BMD T-score, -2.3 +/- 0.7). Men who received strontium ranelate over 2 years had greater increases in lumbar spine BMD than those who received placebo (relative change from baseline to end, 9.7% +/- 7.5% vs 2.0% +/- 5.5%; between-group difference estimate (SE), 7.7% (0.9%); 95% confidence interval, 5.9%-9.5%; P < .001). There were also significant between-group differences in relative changes in femoral neck BMD(P < .001) and total hip BMD (P < .001). At the end of treatment, mean levels of serum cross-linked telopeptides of type I collagen, a marker of bone resorption, were increased in both the strontium ranelate group (10.7% +/- 58.0%; P = .022) and the placebo group (34.9% +/- 65.8%; P < .001). The corresponding mean changes of bone alkaline phosphatase, a marker of bone formation, were 6.4% +/- 28.5% (P = .005) and 1.9% +/- 25.4% (P = .505), respectively. After 2 years, the blood strontium level (129 +/- 66 mu mol/L) was similar to that in trials of postmenopausal osteoporosis. Strontium ranelate was generally well tolerated. Conclusions: The effects of strontium ranelate on BMD in osteoporotic men were similar to those in postmenopausal osteoporotic women, supporting its use in the treatment of osteoporosis in men.
Keywords
FRACTURE RISK REDUCTION, BONE-MINERAL DENSITY, ACID 5 MG, POSTMENOPAUSAL OSTEOPOROSIS, VERTEBRAL FRACTURE, HIP FRACTURE, NONVERTEBRAL FRACTURES, FEMORAL-NECK, DOUBLE-BLIND, WOMEN

Downloads

  • 592.full.Kaufman JM.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 541.89 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Kaufman, Jean, M Audran, G Bianchi, V Braga, M Diaz-Curiel, RM Francis, Stefan Goemaere, et al. 2013. “Efficacy and Safety of Strontium Ranelate in the Treatment of Osteoporosis in Men.” Journal of Clinical Endocrinology & Metabolism 98 (2): 592–601.
APA
Kaufman, J., Audran, M., Bianchi, G., Braga, V., Diaz-Curiel, M., Francis, R., Goemaere, S., et al. (2013). Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 98(2), 592–601.
Vancouver
1.
Kaufman J, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis R, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2013;98(2):592–601.
MLA
Kaufman, Jean, M Audran, G Bianchi, et al. “Efficacy and Safety of Strontium Ranelate in the Treatment of Osteoporosis in Men.” JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM 98.2 (2013): 592–601. Print.
@article{4121854,
  abstract     = {Context: Strontium ranelate reduces vertebral and nonvertebral fracture risk in postmenopausal osteoporosis.
Objective: The objective of this study was to determine the efficacy and safety of strontium ranelate in osteoporosis in men over 2 years (main analysis after 1 year).
Design: This was an international, unbalanced (2: 1), double-blind, randomized placebo-controlled trial (MALEO [MALE Osteoporosis]).
Setting: This international study included 54 centers in 14 countries. 
Participants: Participants were 261 white men with primary osteoporosis. 
Intervention: Strontium ranelate at 2 g/d (n = 174) or placebo (n = 87) was administered.
Main Outcome Measures: Lumbar spine (L2-L4), femoral neck, and total hip bone mineral density (BMD), biochemical bone markers, and safety were measured.
Results: Baseline characteristics were similar in both groups in the whole population (age, 72.9 +/- 6.0 years; lumbar spine BMD T-score, -2.7 +/- 1.0; femoral neck BMD T-score, -2.3 +/- 0.7). Men who received strontium ranelate over 2 years had greater increases in lumbar spine BMD than those who received placebo (relative change from baseline to end, 9.7% +/- 7.5% vs 2.0% +/- 5.5%; between-group difference estimate (SE), 7.7% (0.9%); 95% confidence interval, 5.9%-9.5%; P < .001). There were also significant between-group differences in relative changes in femoral neck BMD(P < .001) and total hip BMD (P < .001). At the end of treatment, mean levels of serum cross-linked telopeptides of type I collagen, a marker of bone resorption, were increased in both the strontium ranelate group (10.7% +/- 58.0%; P = .022) and the placebo group (34.9% +/- 65.8%; P < .001). The corresponding mean changes of bone alkaline phosphatase, a marker of bone formation, were 6.4% +/- 28.5% (P = .005) and 1.9% +/- 25.4% (P = .505), respectively. After 2 years, the blood strontium level (129 +/- 66 mu mol/L) was similar to that in trials of postmenopausal osteoporosis. Strontium ranelate was generally well tolerated.
Conclusions: The effects of strontium ranelate on BMD in osteoporotic men were similar to those in postmenopausal osteoporotic women, supporting its use in the treatment of osteoporosis in men.},
  author       = {Kaufman, Jean and Audran, M and Bianchi, G and Braga, V and Diaz-Curiel, M and Francis, RM and Goemaere, Stefan and Josse, R and Palacios, S and Ringe, JD and Felsenberg, D and Boonen, S},
  issn         = {0021-972X},
  journal      = {JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM},
  keywords     = {FRACTURE RISK REDUCTION,BONE-MINERAL DENSITY,ACID 5 MG,POSTMENOPAUSAL OSTEOPOROSIS,VERTEBRAL FRACTURE,HIP FRACTURE,NONVERTEBRAL FRACTURES,FEMORAL-NECK,DOUBLE-BLIND,WOMEN},
  language     = {eng},
  number       = {2},
  pages        = {592--601},
  title        = {Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men},
  url          = {http://dx.doi.org/10.1210/jc.2012-3048},
  volume       = {98},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: